开云app官网登录入口网页版-官方正版

#APA#

153篇内容 | 3077人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1338255, encodeId=77b5133825525, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Clin Cancer Res：紫杉醇加用Napabucasin治疗晚期胃/胃食管交界腺癌的疗效, objectType=article, longId=734202, objectId=635ae3420254, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=635ae3420254, replyNumber=0, likeNumber=78, createdTime=2022-08-04, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=635ae3420254, moduleTitle=Clin Cancer Res：紫杉醇加用Napabucasin治疗晚期胃/胃食管交界腺癌的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=635ae3420254)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338254, encodeId=72e71338254e8, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=苏爱康医药：日本核准DARVIAS®针剂135毫克（通用名：DARINAPARSIN/开发代码：SP-02）, objectType=article, longId=730161, objectId=38fee301618f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38fee301618f, replyNumber=0, likeNumber=94, createdTime=2022-06-23, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38fee301618f, moduleTitle=苏爱康医药：日本核准DARVIAS®针剂135毫克（通用名：DARINAPARSIN/开发代码：SP-02）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=38fee301618f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338253, encodeId=9f4a133825358, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Clin Cancer Res：紫杉醇联合Napabucasin治疗晚期胃/胃食管交界癌, objectType=article, longId=728684, objectId=ddbfe2868440, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddbfe2868440, replyNumber=0, likeNumber=86, createdTime=2022-06-07, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddbfe2868440, moduleTitle=Clin Cancer Res：紫杉醇联合Napabucasin治疗晚期胃/胃食管交界癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ddbfe2868440)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338252, encodeId=11f01338252fc, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=ASCO：适应性体育活动显著改善晚期胰腺癌(APACaP)患者的生活质量, objectType=article, longId=728268, objectId=918ae28268b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=918ae28268b7, replyNumber=0, likeNumber=91, createdTime=2022-06-01, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=918ae28268b7, moduleTitle=ASCO：适应性体育活动显著改善晚期胰腺癌(APACaP)患者的生活质量, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=918ae28268b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338251, encodeId=bdee1338251a6, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Eur Heart J：Ciraparantag能逆转阿哌沙班和利伐沙班的抗凝血活性, objectType=article, longId=726143, objectId=45b7e2614314, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45b7e2614314, replyNumber=0, likeNumber=97, createdTime=2022-05-06, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45b7e2614314, moduleTitle=Eur Heart J：Ciraparantag能逆转阿哌沙班和利伐沙班的抗凝血活性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=45b7e2614314)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338250, encodeId=a9b813382509d, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS, objectType=article, longId=302295, objectId=5d50302295d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d50302295d1, replyNumber=0, likeNumber=75, createdTime=2022-04-04, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d50302295d1, moduleTitle=PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5d50302295d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338249, encodeId=fe0713382492c, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=NEJM：RESCUE-Japan LIMIT研究：大面积急性缺血性卒中患者血管内治疗的功能预后优于单纯药物治疗, objectType=article, longId=295515, objectId=29cd2955155a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29cd2955155a, replyNumber=0, likeNumber=73, createdTime=2022-02-14, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29cd2955155a, moduleTitle=NEJM：RESCUE-Japan LIMIT研究：大面积急性缺血性卒中患者血管内治疗的功能预后优于单纯药物治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=29cd2955155a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338248, encodeId=4ed413382481a, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=指南共识｜慢性乙型肝炎患者如何停药、停药后如何复查——APASL指导意见, objectType=article, longId=295415, objectId=c67e2954154b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c67e2954154b, replyNumber=0, likeNumber=83, createdTime=2022-02-12, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c67e2954154b, moduleTitle=指南共识｜慢性乙型肝炎患者如何停药、停药后如何复查——APASL指导意见, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c67e2954154b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338247, encodeId=2392133824e18, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=2022 APASL指南：妊娠期HBV感染, objectType=article, longId=295390, objectId=6aef29539049, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aef29539049, replyNumber=0, likeNumber=63, createdTime=2022-02-12, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aef29539049, moduleTitle=2022 APASL指南：妊娠期HBV感染, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6aef29539049)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338246, encodeId=7306133824605, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA, objectType=article, longId=295346, objectId=6f04295346b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f04295346b6, replyNumber=0, likeNumber=0, createdTime=2022-02-11, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f04295346b6, moduleTitle=Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6f04295346b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338245, encodeId=709b133824559, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Clin Cancer Res：mTOR抑制剂sapanisertib联合氟维司群治疗芳香化酶抑制剂进展后ER+/ HER2-的绝经后女性晚期乳腺癌患者的疗效, objectType=article, longId=293538, objectId=db002935384a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db002935384a, replyNumber=0, likeNumber=79, createdTime=2022-01-08, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db002935384a, moduleTitle=Clin Cancer Res：mTOR抑制剂sapanisertib联合氟维司群治疗芳香化酶抑制剂进展后ER+/ HER2-的绝经后女性晚期乳腺癌患者的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=db002935384a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338244, encodeId=169913382440e, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=辉瑞的DMD基因疗法fordadistrogene movaparvovec在患者死亡后被FDA搁置, objectType=article, longId=292791, objectId=e037292e9125, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e037292e9125, replyNumber=0, likeNumber=93, createdTime=2021-12-28, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e037292e9125, moduleTitle=辉瑞的DMD基因疗法fordadistrogene movaparvovec在患者死亡后被FDA搁置, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e037292e9125)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338243, encodeId=6fed1338243fe, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=《APASL慢性乙型肝炎患者停用核苷(酸)类似物指导意见》解读, objectType=article, longId=221447, objectId=481522144ecd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=481522144ecd, replyNumber=0, likeNumber=63, createdTime=2021-12-04, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=481522144ecd, moduleTitle=《APASL慢性乙型肝炎患者停用核苷(酸)类似物指导意见》解读, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=481522144ecd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338242, encodeId=bcf3133824299, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Oncologist: Apatinib（阿帕替尼）与S-1联合一线治疗晚期胃癌疗效和安全性, objectType=article, longId=221378, objectId=de1e2213e8db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de1e2213e8db, replyNumber=0, likeNumber=142, createdTime=2021-12-02, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de1e2213e8db, moduleTitle=Oncologist: Apatinib（阿帕替尼）与S-1联合一线治疗晚期胃癌疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=de1e2213e8db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338241, encodeId=b0931338241c7, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Eur J Cancer：Rucaparib治疗BRCA1/2野生型转移性乳腺癌的疗效, objectType=article, longId=221327, objectId=bdda22132edc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdda22132edc, replyNumber=0, likeNumber=114, createdTime=2021-12-01, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdda22132edc, moduleTitle=Eur J Cancer：Rucaparib治疗BRCA1/2野生型转移性乳腺癌的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bdda22132edc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338240, encodeId=7e97133824018, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究, objectType=article, longId=221311, objectId=7491221311ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7491221311ab, replyNumber=0, likeNumber=84, createdTime=2021-12-01, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7491221311ab, moduleTitle=Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7491221311ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338233, encodeId=44a01338233b4, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=JAMA Cardiology：达格列净对射血分数降低心衰安全有效（DAPA-HF研究）, objectType=article, longId=253417, objectId=a50b25341e62, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a50b25341e62, replyNumber=0, likeNumber=73, createdTime=2021-11-07, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a50b25341e62, moduleTitle=JAMA Cardiology：达格列净对射血分数降低心衰安全有效（DAPA-HF研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a50b25341e62)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338239, encodeId=8de71338239f6, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Kidney Int ：达格列净和预防慢性肾脏疾病不良结局(DAPA-CKD)预先指定分析对肾功能突然下降发生率的随机对照试验研究, objectType=article, longId=219739, objectId=7991219e39e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7991219e39e7, replyNumber=0, likeNumber=79, createdTime=2021-11-05, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7991219e39e7, moduleTitle=Kidney Int ：达格列净和预防慢性肾脏疾病不良结局(DAPA-CKD)预先指定分析对肾功能突然下降发生率的随机对照试验研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7991219e39e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338238, encodeId=6dbf1338238f5, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=LDE：在DAPA-CKD试验中，通过蛋白尿和eGFR斜率预测治疗反应, objectType=article, longId=219695, objectId=e984219695dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e984219695dd, replyNumber=0, likeNumber=89, createdTime=2021-11-04, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e984219695dd, moduleTitle=LDE：在DAPA-CKD试验中，通过蛋白尿和eGFR斜率预测治疗反应, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e984219695dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338237, encodeId=d6ae133823eba, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Lancet Neurol：荷兰心房颤动患者抗凝相关脑出血后阿匹沙班与不抗凝的比较(APACHE-AF), objectType=article, longId=219387, objectId=5cac21938e87, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cac21938e87, replyNumber=0, likeNumber=79, createdTime=2021-10-29, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cac21938e87, moduleTitle=Lancet Neurol：荷兰心房颤动患者抗凝相关脑出血后阿匹沙班与不抗凝的比较(APACHE-AF), moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5cac21938e87)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

APA

2020-05-29

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Clin Cancer Res：紫杉醇加用Napabucasin治疗晚期胃/胃食管交界腺癌的疗效

2022-08-04

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

苏爱康医药：日本核准DARVIAS®针剂135毫克（通用名：DARINAPARSIN/开发代码：SP-02）

2022-06-23

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Clin Cancer Res：紫杉醇联合Napabucasin治疗晚期胃/胃食管交界癌

2022-06-07

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

ASCO：适应性体育活动显著改善晚期胰腺癌(APACaP)患者的生活质量

2022-06-01

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Eur Heart J：Ciraparantag能逆转阿哌沙班和利伐沙班的抗凝血活性

2022-05-06

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS

2022-04-04

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

NEJM：RESCUE-Japan LIMIT研究：大面积急性缺血性卒中患者血管内治疗的功能预后优于单纯药物治疗

2022-02-14

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

指南共识｜慢性乙型肝炎患者如何停药、停药后如何复查——APASL指导意见

2022-02-12

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

2022 APASL指南：妊娠期HBV感染

2022-02-12

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA

2022-02-11

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Clin Cancer Res：mTOR抑制剂sapanisertib联合氟维司群治疗芳香化酶抑制剂进展后ER+/ HER2-的绝经后女性晚期乳腺癌患者的疗效

2022-01-08

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

辉瑞的DMD基因疗法fordadistrogene movaparvovec在患者死亡后被FDA搁置

2021-12-28

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

《APASL慢性乙型肝炎患者停用核苷(酸)类似物指导意见》解读

2021-12-04

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Oncologist: Apatinib（阿帕替尼）与S-1联合一线治疗晚期胃癌疗效和安全性

2021-12-02

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Eur J Cancer：Rucaparib治疗BRCA1/2野生型转移性乳腺癌的疗效

2021-12-01

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究

2021-12-01

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

JAMA Cardiology：达格列净对射血分数降低心衰安全有效（DAPA-HF研究）

2021-11-07

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Kidney Int ：达格列净和预防慢性肾脏疾病不良结局(DAPA-CKD)预先指定分析对肾功能突然下降发生率的随机对照试验研究

2021-11-05

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

LDE：在DAPA-CKD试验中，通过蛋白尿和eGFR斜率预测治疗反应

2021-11-04

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Lancet Neurol：荷兰心房颤动患者抗凝相关脑出血后阿匹沙班与不抗凝的比较(APACHE-AF)

2021-10-29

科室
- - 订阅+
  - 更多科室
工具
服务